OraSure Technologies, Inc. Appoints Vice President, Corporate Communications

BETHLEHEM, Pa., July 23, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostics and specimen collection devices, today announced that Jeanne Mell has been appointed as the Company’s new Vice President, Corporate Communications. Ms. Mell will join OraSure on August 13, 2018.

Most recently, Ms. Mell served as Vice President Marketing Communications at the University City Science Center in Philadelphia, where she was responsible for corporate marketing, program development, communications, public and media relations and community engagement. Ms. Mell also launched Quorum, the Science Center’s clubhouse for entrepreneurs, and the Science Center’s Innovators Walk of Fame.  

Immediately before joining the Science Center, Ms. Mell was Senior Vice President, Communications for the Delaware State Chamber of Commerce. Prior to joining the Chamber, Ms. Mell had a career in journalism at The News Journal in Delaware, the Associated Press in New York and Philadelphia, ABC News, Good Morning America and Popular Photography Magazine. She started her career at Inc. Magazine.

Ms. Mell is the immediate past chair of Campus Philly and also served as Vice President of the Association of University Research Parks.

Ms. Mell is a graduate of the University of California, Santa Cruz.

“We are delighted to welcome Jeanne as the Company’s new Vice President, Corporate Communications. Jeanne’s extensive communications expertise in conjunction with her public and media relations experience will play a key role in reinforcing and augmenting OraSure’s corporate identity and thought leadership within the global community,” said Stephen S. Tang, Ph.D., President and CEO of OraSure Technologies. 

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick^® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.  For more information on OraSure Technologies, please visit www.orasure.com.

Company contact: